Management of cutaneous T cell lymphoma: new and emerging targets and treatment options

• Main Authors: Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C
• Format: Article
• Language: English
• Published: Dove Medical Press 2012-03-01
• Series: Cancer Management and Research
• Online Access: http://www.dovepress.com/management-of-cutaneous-t-cell-lymphoma-new-and-emerging-targets-and-t-a9458

Janet Y Li1, Steven Horwitz2, Alison Moskowitz2, Patricia L Myskowski3, Melissa Pulitzer4, Christiane Querfeld31College of Physicians and Surgeons, Columbia University, 2Department of Medicine, Lymphoma Service, 3Department of Medicine, Dermatology Service, 4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAAbstract: Cutaneous T cell lymphomas (CTCL) clinically and biologically represent a heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the most common subtypes. Over the last decade, new immunological and molecular pathways have been identified that not only influence CTCL phenotype and growth, but also provide targets for therapies and prognostication. This review will focus on recent advances in the development of therapeutic agents, including bortezomib, the histone deacetylase inhibitors (vorinostat and romidepsin), and pralatrexate in CTCL.Keywords: novel targets, histone deacetylase inhibitors, pralatrexate, bortezomib, cutaneous T cell lymphoma